Seeking Alpha

Athersys (ATHX) +200% after inking a deal with Pfizer (PFE) to develop and market its...

Athersys (ATHX) +200% after inking a deal with Pfizer (PFE) to develop and market its experimental stem cell therapy MultiStem. Pfizer will pay $6M up front, fund the drug's R&D, and pay up to $105M on milestones.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|